PDB36 LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72094-0
https://www.valueinhealthjournal.com/article/S1098-3015(11)72094-0/fulltext
Title :
PDB36 LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72094-0&doi=10.1016/S1098-3015(11)72094-0
First page :
A290
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
254